Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still cancer-free years later in a small

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report.

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune response in all nine patients at high risk for recurrences of their cancer.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report. The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their tumors,

Doctors at Dana-Farber say this personalized vaccine can be given after surgery to remove a tumor and train the body’s immune system to eliminate tumor cells.